ArticleACS omega2024
Kinetics and Optimization Studies of Controlled 5-Fluorouracil Release from Graphene Oxide Incorporated Vegetable Oil-Based Polyurethane Composite Film.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study focuses on investigating the potential of produced graphene oxide (GO)/oil-based polyurethane composite films as a drug carrier for 5-fluorouracil (5-FU). Polyurethane was synthesized starting from blends of castor oil and sunflower oil-based glyceride, followed by GO and 5-FU anticancer drug bearing film production by solution casting. GO/PU composite film samples were characterized by FTIR, TGA and SEM analysis, confirming the PU production and distribution of 5-FU drug at a homogeneous level in GO/PU films. Experimental design studies were carried out to provide insight into the influence of GO incorporation, the amount of loaded drug, and the release medium pH value on 5-FU release behavior. The amount of 5-FU delivered from GO/PU composites displayed a tendency to increase at high GO ratios and high pH values, with the obtained maximum ratio of 91.4%. From release kinetics studies, the pH-sensitive behavior of GO/PU composites was observed following a Higuchi or zero-order kinetic model depending on the GO ratio, indicating a sustained release of the drug. The in vitro cytotoxicity effect of GO/PU film through 5-FU drug release was confirmed against the MCF-7 human breast cancer cell line, while good biocompatibility of the drug-free GO/PU film against the L-929 mouse fibroblast cell line was confirmed via MTT assay test. Overall, the findings support that produced GO/PU composites hold potential for clinical drug delivery applications as a 5-FU drug carrier.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.